28 registrations that name nicotinamide riboside as a study arm and are recruiting or about to, as ClinicalTrials.gov listed them on Oct 20, 2026. Read each listing for its full criteria and current status.
Kymata never assesses eligibility. Each listing names its own criteria; only its study team can say whether someone can join. Trial doses are given under the trial's monitoring and are not a schedule for anyone outside it.
Filter 28 registrations
Status
Phase
20US sites across 12 states
1
2 to 4
5 to 19
20 or more
All 28 registrations
RecruitingNCT05194397
Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors
Phase 2
Children's Hospital of Philadelphia
About 80 people
Started Feb 23, 2023
In plain words A Phase 2 study of nicotinamide riboside in people 10 to 30, run by Children's Hospital of Philadelphia. It plans to enroll about 80 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 10 to 30. Conditions: Lymphoblastic Leukemia; Cancer Survivors; Aplastic Anemia; Myelodysplastic Syndromes; Myeloid Leukemia.
Males and females, ages 10-30 years at enrollment
Able to understand and speak English
Diagnosis of leukemia (myeloid, lymphoid), aplastic anemia, bone marrow failure syndrome, or myelodysplastic syndrome requiring allogeneic HCT
6-48 months from allogeneic HCT
3 more inclusion criteria and the exclusion criteria are on the listing.
This will be a randomized, placebo-controlled trial with a 2x2 factorial design testing the effects of an NAD+ precursor (NR) and exercise on skeletal muscle quality and VO2max in AYA HCT survivors. The primary outcome is the change in muscle strength (isometric knee extension) from baseline to 16 weeks. The full summary is on the listing.
Where, as registered
3 US sites in 3 states.
RecruitingNCT05500170
Benefits of Nicotinamide Riboside Upon Cognition and Sleep
No phase
State University of New York at Buffalo
About 50 people
Started Apr 4, 2023
In plain words A study of nicotinamide riboside in people 65 to 85, run by State University of New York at Buffalo. It plans to enroll about 50 people at 3 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 65 to 85; healthy volunteers accepted. Conditions: Cognitive Impairment; Sleep Quality.
Sleep Quality. Pittsburgh Sleep Quality Index (PSQI) global score >5
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide riboside; Placebo
Registered summary
Poor sleep quality and short sleep duration may be a mechanistic component of cognitive impairment in older adults, associated with a decline in brain-derived neurotrophic factor. Increasing the availability of nicotinamide adenine dinucleotide (NAD+) with supplementation of its precursor, nicotinamide riboside (NR), a form of vitamin B3 may increase the expression of brain-derived neurotrophic factor. The full summary is on the listing.
Where, as registered
3 US sites in 1 state.
RecruitingNCT05243290
Nicotinamide Riboside Clinical Trial for GWI
No phase
Roskamp Institute Inc.
About 52 people
Started Apr 13, 2022
In plain words A study of nicotinamide riboside in people 47 to 70, run by Roskamp Institute Inc.. It plans to enroll about 52 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 47 to 70. Conditions: Gulf War Illness.
Both sexes, all ethnic groups, and ages 47 to 70 years.
Subject willing and able to give informed consent.
Medically stable as per the investigator's discretion.
Negative urine pregnancy test for females of childbearing potential. A woman is considered of childbearing potential unless she is surgically sterile (hysterectomy or tubal ligation) or is postmenopausal (no menstrual cycle for 2 years or…
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Placebo
Registered summary
In this multi-site trial, we will use a randomized, double-blind, placebo-controlled study design to test whether 300 mg of Nicotinamide Riboside (NR) can achieve the primary objective of increasing plasma NAD+ levels in participants with Gulf War Illness (GWI).
Where, as registered
2 US sites in 1 state.
RecruitingNCT07073352
ACEs, SIRT1, and Premature Vascular Aging in Humans
No phase
University of Wisconsin, Madison
About 30 people
Started Mar 27, 2025
In plain words A study of nicotinamide riboside in people 18 to 30, run by University of Wisconsin, Madison. It plans to enroll about 30 people at 2 US sites.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 30; healthy volunteers accepted. Conditions: Adverse Childhood Experiences; Endothelial Dysfunction.
18 - 30 years
ACE score of 0 OR ≥4 (Aim 1); ACE score ≥4 (Aim 2)
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Placebo
Registered summary
Adverse childhood experiences (ACEs) are directly related to cardiovascular morbidity and mortality, and impaired vascular endothelial function (VEF) is an independent predictor of future cardiovascular disease (CVD) risk \[1, 2\]. Previous work from our lab (IRB 202010095) and others \[3\] demonstrates impaired VEF in young adults with prior exposure to ACEs even in the absence of clinical CVD risk factors. The full summary is on the listing.
Where, as registered
2 US sites in 2 states.
RecruitingNCT05483465
The Effect of NAD Supplementation on Brain Vascular Health in Aging
Phase 4
University of Oklahoma
About 214 people
Started May 3, 2023
In plain words A Phase 4 study of nicotinamide riboside in people 60 to 85, run by University of Oklahoma. It plans to enroll about 214 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 85; healthy volunteers accepted. Conditions: Aging.
Age ≥60 and ≤85 years of age
Adequate hearing and visual acuity to participate in the examinations
Ability to read and write in English
Competence to provide informed consent.
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide riboside; Placebo
Registered summary
Daily consumption of one of the forms of Vitamin B3, the Nicotinamide Riboside (NR), energizes the body and combats cellular aging. This study is designed to test whether NR can also improve brain health and memory.
Where, as registered
1 US site in 1 state.
RecruitingNCT06044935
Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate
No phase
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
About 100 people
Started Jan 8, 2024
In plain words A study of nicotinamide riboside in people 18 to 65, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). It plans to enroll about 100 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 65. Conditions: Overweight; Obesity.
Meet one of the following:
Adult males aged 18-65 years
Pre-menopausal adult females aged 18-50 years
Adult males aged 18-65 years with diagnosed maturity-onset diabetes of the young type 2 (MODY2) or pre-menopausal adult females aged 18-50 years with diagnosed MODY2
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Standard Diet; Ketogenic Diet; Placebo; Nicotinamide Riboside
Registered summary
Background: At least 30% of Americans have fatty liver disease. This means that they store too much fat in the liver. At the moment lifestyle changes are the only way to treat this problem. Objective: To test how (1) a low-carbohydrate diet and (2) a supplement called nicotinamide riboside (NR) affect how a person s body uses dietary fat. Eligibility: Men aged 18 to 65 and women aged 18 to 50 who are healthy volunteers with a body mass index (height to weight ratio) of 25 or more. Adults with maturity-onset diabetes of the young type 2 (MODY2) are also needed. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06032923
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
Phase 1 and 2
National Heart, Lung, and Blood Institute (NHLBI)
About 78 people
Started Mar 13, 2024
In plain words A Phase 1 and 2 study of nicotinamide riboside in female participants 18 to 120, run by National Heart, Lung, and Blood Institute (NHLBI). It plans to enroll about 78 people at 1 US site.
Female subjects 18 years or older who meets > 3 of 11 modified Am. Coll. of Rheumatology (ACR) (1997) Revised Criteria for SLE and mild/moderate disease activity defined as an SLE Disease Activity Index 2000(SLEDAI 2K) between zero and…
If on glucocorticoids, the dose must be less than or equal to 20 mg daily and stable for at least 4 weeks prior to screening;
If on hydroxychloroquine or other antimalarials such as chloroquine or quinacrine, dose must have been stable for the 12 weeks prior to screening. The max.
If on immunosuppressive drugs (methotrexate, azathioprine, mycophenolate mofetil, cyclosporine, tacrolimus); dose must have been stable for the 12 weeks prior to screening
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside
Registered summary
Study Description: Systemic lupus erythematosus (SLE) occurs predominantly in women and is driven by type I interferon dysregulation and neutrophil hyperresponsiveness. Neutrophils in females have reduced mitochondrial bioenergetic capacity which affects immunometabolism. Nicotinamide adenine dinucleotide (NAD)+ boosting with nicotinamide riboside blunts type 1 IFN activation in-vivo in monocytes of healthy subjects and ex-vivo in SLE subjects. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT06567717
Zinc and Nicotinamide Riboside for Idiopathic Pulmonary Fibrosis
Phase 2
Cedars-Sinai Medical Center
About 60 people
Started Nov 3, 2025
In plain words A Phase 2 study of nicotinamide riboside in people 50 and older, run by Cedars-Sinai Medical Center. It plans to enroll about 60 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Idiopathic Pulmonary Fibrosis.
Provision of signed and dated informed consent form
Stated willingness to comply with all study procedures and availability for the duration of the study
Be under active treatment for IPF by a local pulmonologist
Age \> 50 years
11 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Zinc; Placebos for zinc and nicotinamide riboside; Nicotinamide riboside
Registered summary
The goal of this clinical trial is to learn if a clinical trial for idiopathic pulmonary fibrosis (IPF) can recruit and retain participants from their home to study whether a combination of zinc and nicotinamide riboside can treat iIPF. The main questions are: Can the investigators recruit participants, and can participants complete study procedures without physically coming into specific clinical trial sites? Can people with IPF experience improvement in symptoms, quality of life, or functioning if they are take these supplements? The investigators will compare zinc and nicotinamide riboside… The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT04614714
Milk Volume Outcomes Following Oral Nicotinamide Riboside Supplementation in Mothers of Extremely Preterm Infants
Phase 2 and 3
University of California, Davis
About 40 people
Started Aug 19, 2026
In plain words A Phase 2 and 3 study of nicotinamide riboside in female participants 18 and older, run by University of California, Davis. It plans to enroll about 40 people at 1 US site.
This study aims to evaluate the feasibility and effects of nicotinamide riboside (NR) supplementation in lactating mothers of infants expected to be hospitalized in the neonatal intensive care unit (NICU) for at least four weeks.
Where, as registered
1 US site in 1 state.
RecruitingNCT04332341
Study of Nicotinamide Riboside Supplementation in Allogeneic Hematopoietic Cell Transplantation
Early phase 1
Case Comprehensive Cancer Center
About 20 people
Started May 19, 2020
In plain words An early phase 1 study of nicotinamide riboside in people 18 and older, run by Case Comprehensive Cancer Center. It plans to enroll about 20 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Allogeneic Hematopoietic Cell Transplantation.
All disease indications for allogeneic hematopoietic cell transplantation except for myelofibrosis.
Subject must meet program eligibility criteria* for myeloablative conditioning alloHCT and plan to undergo myeloablative conditioning.
HLA-identical related donor or unrelated human donor source with bone marrow graft.
Subjects must provide a written informed consent.
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide riboside (NR)
Registered summary
The purpose of this study is to find a safe and tolerable way to improve engraftment after transplant. Research studies have shown that adding nicotinamide riboside to donor cells has the potential to increase blood stem cell numbers and potentially decrease the time to engraftment. Also, nicotinamide riboside, TRU NIAGEN (the study drug) is a type of vitamin B supplement that the general public can get without a prescription and is well tolerated.
Where, as registered
1 US site in 1 state.
RecruitingNCT06280482
Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)
Phase 1
The University of Texas Health Science Center, Houston
About 15 people
Started Mar 6, 2024
In plain words A Phase 1 study of nicotinamide riboside in people 1 and older, run by The University of Texas Health Science Center, Houston. It plans to enroll about 15 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 1 and older. Conditions: Smooth Muscle Dysfunction Syndrome (SMDS).
Individuals diagnosed with SMDS with confirmed ACTA2 mutation disrupting arginine 179
Parental/guardian permission (informed consent) and, if appropriate, child assent.
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide riboside (NR)
Registered summary
The purpose of this study is to determine whether SMDS patients treated with NR at the proposed dose exhibit decreased glucose uptake in the aorta, to determine if NR treatment results in measurable changes of blood NAD+ and NR levels, to determine if aortic measurements are stable after treatment with NR and to evaluate the safety and tolerability of NR in SMDS patients.
Where, as registered
1 US site in 1 state.
RecruitingNCT07563322
Mechanistic Study of Nicotinamide Riboside on NAD+ Biology in Individuals With Combined Pulmonary Hypertension
No phase
Vanderbilt University Medical Center
About 10 people
Started Apr 9, 2026
In plain words A study of nicotinamide riboside in people 18 to 85, run by Vanderbilt University Medical Center. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 85. Conditions: Pulmonary Hypertension.
Aged >/= 18 to 85 years of age
Diagnosis of Combined pre-/post-capillary PH (CPH) defined as mean pulmonary artery pressure >20mmHg, pulmonary capillary wedge pressure >15mmHg, and pulmonary vascular resistance ³3 Wood units
NYHA Class I - III
A qualifying Baseline RHC performed within 2 years of consent Clinical echocardiogram within the prior year with LVEF>/= 45%
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
Pulmonary hypertension (PH) is a serious condition that puts strain on the heart and lungs and often leads to frequent hospital stays and shortened life expectancy. The most common cause is heart disease affecting the left side of the heart. A particularly high-risk form, called combined pre- and post-capillary pulmonary hypertension (CPH), occurs in about one in four people with heart failure. There are currently no approved treatments for CPH, and many patients develop right-sided heart failure and die earlier than expected. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
RecruitingNCT07579429
Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)
Phase 2
University of Colorado, Denver
About 10 people
Started May 20, 2026
In plain words A Phase 2 study of nicotinamide riboside in people 18 and older, run by University of Colorado, Denver. It plans to enroll about 10 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Clonal Cytopenia of Undetermined Significance; Myelodysplastic Syndrome.
Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed procedures.
Stated willingness to comply with all study procedures and be available for the duration of the study.
Be a male or female aged ≥ 18 years of age.
For persons of reproductive potential, use of highly effective method(s) of contraception.
8 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Pterostilbene
Registered summary
This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are: * to assess if study drug improves cytopenias in patients * to determine safety of the study drug in patients
Where, as registered
1 US site in 1 state.
RecruitingNCT06162013
The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism
Phase 2
Haukeland University Hospital
About 330 people
Started Mar 5, 2024
In plain words A Phase 2 study of nicotinamide riboside in people 30 to 85, run by Haukeland University Hospital. It plans to enroll about 330 people at 3 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 85. Conditions: Progressive Supranuclear Palsy; Multiple System Atrophy; Corticobasal Syndrome.
Participant must understand the nature of the study and be able to provide written, informed consent.
Male or female aged 30-85 years at baseline.
123I-Ioflupane dopamine transporter imaging (DaTSCAN) or FDOPA- PET has been performed. A negative DaTSCAN cannot be more than two years old at baseline.
Meet the MDS criteria for possible or probable PSP; or
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Placebo
Registered summary
Progressive supranuclear palsy (PSP), Multiple system atrophy (MSA) and corticobasal syndrome (CBS) are severe neurodegenerative diseases with rapid progression and no effective treatment. Patients quickly succumb to increasing motor and non-motor symptoms and survival ranges from \~3 years to \~10 years. Although PSP, MSA and CBS are rare diseases they constitute a major and mostly unaddressed challenge to health-care providers due to the severity of disease and lack of treatment. The full summary is on the listing.
Where, as registered
No US site; Norway (3).
RecruitingNCT07741071
N-AD: Orally Administered Nicotinamide Riboside Over Two Years as a Potential Disease Modifying Treatment for Alzheimer's Disease
Phase 2
Haukeland University Hospital
About 270 people
Starts Aug 26, 2026 (estimated)
In plain words A Phase 2 study of nicotinamide riboside in people 50 to 85, run by Haukeland University Hospital. It plans to enroll about 270 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 50 to 85. Conditions: Alzheimer Disease (AD).
Diagnosis Early clinical AD, e.g. Stage 3 MCI or Stage 4 (mild AD dementia), as defined by the FDA, 2024.
Biomarker evidence consistent with AD neuropathologic change, defined by CSF markers, i.e. Aβ42 < 1030 ng/L and P-tau181/Aβ42 > 0,023 ng/L and/or T-tau/Aβ42 > 0,28 ng/L* or AD amyloid biomarker (as determined either by visual reading of…
Diagnosed with AD within 2 years from baseline.
Capacity to provide written informed consent for study participation defined as Montreal Cognitive Assessment (MoCA) score ≥ 16 or Mini Mental State Evaluation (MMSE) score ≥ 20.
4 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Palacebo
Registered summary
The goal of this clinical trial is to learn if orally administered nicotinamide riboside works to slow the progression of early Alzheimer disease in adults. It will also learn about the safety of drug nicotinamide riboside. The main questions it aims to answer are: * Does drug nicotinamide riboside slow the progression of Alzheimer disease as measured by the Clinical Dementia Rating scale. The full summary is on the listing.
Where, as registered
No US site; Norway (2).
RecruitingNCT06587945
Nicotinamide Riboside Oral Supplementation in Macula Off Retinal Detachment
Phase 4
Center for Eye Research Australia
About 144 people
Started Sep 19, 2025
In plain words A Phase 4 study of nicotinamide riboside in people 18 and older, run by Center for Eye Research Australia. It plans to enroll about 144 people at 5 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Retinal Detachment.
Age ≥ 18 years old
Able to give informed consent and comply with all study visits and procedures.
Present within 10 days of macula-off retinal detachment (based on patient-reported history of loss of central vision)
Present to the hospital with a visual acuity of hand motion or better in the study eye
12 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Placebo; Vitrectomy and Gas tamponade
Registered summary
Retinal detachment occurs when fluid separates the retina (a thin, light sensing tissue) from its usual attachment at the back of the eye. If detached, these retinal cells lose their normal blood supply and begin to die, which is the primary cause of vision loss in retinal detachment. The 'macula' refers to the very centre of the retina, with the highest density of retinal cells, most responsible for vision. Significant vision loss occurs when this part of the retina becomes separated (termed a 'macula-off retinal detachment'). Typically, surgery is required to repair the retinal detachment. The full summary is on the listing.
Where, as registered
No US site; Australia (5).
RecruitingNCT06991712
Comparisons of NAD Precursors for Neuroenhancement in Glaucoma Patients
Phase 2
Christopher Kai Shun Leung
About 138 people
Started May 19, 2025
In plain words A Phase 2 study of nicotinamide riboside in people 18 and older, run by Christopher Kai Shun Leung. It plans to enroll about 138 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 and older. Conditions: Glaucoma.
glaucoma patients
age ≥ 18 years
best corrected VA ≥20/40
IOP <21 mmHg
1 more inclusion criterion and the exclusion criteria are on the listing.
The goal of this clinical trial is to determine whether oral supplementation with different nicotinamide adenine dinucleotide (NAD) precursors can improve visual function in adults with primary open-angle glaucoma. The main questions it aims to answer are: 1. Does daily oral administration of equimolar doses of nicotinamide riboside (NR), nicotinamide (NAM), nicotinamide mononucleotide (NMN), or nicotinic acid (NA) improve visual field sensitivity in glaucoma patients over the short term? 2. The full summary is on the listing.
Where, as registered
No US site; Hong Kong (1).
RecruitingNCT06853743
The NAD-HD Study: A Study to Investigate Efficacy and Safety of Nicotinamide Riboside Compared With Placebo in Huntington's Disease
Phase 2
Oslo University Hospital
About 120 people
Starts Mar 18, 2025 (estimated)
In plain words A Phase 2 study of nicotinamide riboside in people 18 to 80, run by Oslo University Hospital. It plans to enroll about 120 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80. Conditions: Huntington Disease.
Confirmed HD gene expansion carrier status with a diagnostic genetic test confirming ≥36 CAG-repeats in HTT.
Clinically manifest HD with objective neurological signs corresponding to Diagnostic Confidence Level 4 based on the Total Motor Score of the UHDRS.
Early or mid-stage disease corresponding to Shoulson-Fahn stage 1-340 and Total Functional Capacity (TFC) > 2.
Ability to walk indoors unassisted or by the help of walking aids only as determined at screening and baseline visits.
5 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
The goal of this clinical trial is to learn if oral supplement of nicotinamide riboside (NR), a form of vitamin B3, slows disease progression in adults with Huntington's disease. It will also learn about the safety of nicotinamide riboside. The main questions it aims to answer are: * Does NR slow progression of overall symptom burden in Huntington's disease? * Does NR have an effect on any specific symptom domain in Huntington's disease? * Does supplementation with NR cause side-effects or safety issues when used for 2 years in Huntington's disease? * Does NR have an effect on selected blood,… The full summary is on the listing.
Where, as registered
No US site; Norway (1).
RecruitingNCT06208527
The NADage Study: Nicotinamide Riboside Replenishment Therapy Against Functional Decline in Aging
Phase 2
Haukeland University Hospital
About 100 people
Starts Jan 2025 (estimated)
In plain words A Phase 2 study of nicotinamide riboside in people 75 and older, run by Haukeland University Hospital. It plans to enroll about 100 people at 2 sites, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 75 and older. Conditions: Frailty; Frail Elderly Syndrome; Frailty Syndrome; Aging.
Participant must understand the nature of the study and be able to provide written, informed consent.
Male or female aged ≥ 75 years at baseline.
Fried Frailty Phenotype score ≥ 3 to identify frail individuals.
Montreal Cognitive Assessment (MoCA) at screening adjusted to age, gender, and educational level, with a threshold set at the 10th percentile (z-score ≤ -1.28).
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
This clinical study, designed as a double-blind, randomized, placebo-controlled trial, aims to investigate the potential of nicotinamide riboside (NR) to decelerate functional decline in the elderly frail population. In animal studies, NR, which is converted to nicotinamide adenine dinucleotide (NAD), has shown potential as a neuroprotective agent, with indications of protection against amyotrophic lateral sclerosis (ALS), Alzheimer's dementia, and Parkinson's disease. The full summary is on the listing.
Where, as registered
No US site; Norway (2).
RecruitingNCT06627868
Nicotinamide Adenine Dinucleotide (NAD+) Metabolism in Human Brown Adipose Tissue
No phase
University of Turku
About 68 people
Started Nov 20, 2024
In plain words A study of nicotinamide riboside in people 30 to 65, run by University of Turku. It plans to enroll about 68 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 30 to 65; healthy volunteers accepted. Conditions: Obesity, Abdominal.
Willingness to provide informed consent to participate in the BATNAD study
Must be able to read and speak English/Finnish/Swedish well enough to completely understand the instructions and provide informed consent
Age 30-55 (sedentary lifestyle)
BMI = 18-25 kg/m2 (normal-weight subjects)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
NAD+ precursor; Placebo
Registered summary
A fully functional brown fat helps maintain a healthy weight and decreases the risk of metabolic diseases such as type II diabetes (T2DM). Unfortunately, in human adults, the functionality of brown fat declines with age, and it is one of the reasons for gaining unhealthy weight, particularly around the waistline (central obesity). Currently, scientists do not clearly understand the reasons for the decline in brown fat functionality. The full summary is on the listing.
Where, as registered
No US site; Finland (1).
RecruitingNCT05732051
Nicotinamide Riboside and Prevention of Cancer Therapy Related Cardiac Dysfunction in Breast Cancer Patients
Phase 2
University Hospital, Akershus
About 60 people
Started Mar 16, 2023
In plain words A Phase 2 study of nicotinamide riboside in female participants 18 and older, run by University Hospital, Akershus. It plans to enroll about 60 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists female participants 18 and older. Conditions: Breast Cancer; Metastatic Breast Cancer; Cancer Therapy-Related Cardiac Dysfunction; Cardiotoxicity; Heart Failure.
Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy
Eastern Cooperative Oncology Group performance status 0-2
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside; Placebo
Registered summary
Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
Where, as registered
No US site; Norway (1).
RecruitingNCT06425042
Nicotinamide Riboside Supplementation and Exercise Training to Promote Healthy Longevity
No phase
Finis Terrae University
About 28 people
Started Mar 1, 2024
In plain words A study of nicotinamide riboside in people 60 to 80, run by Finis Terrae University. It plans to enroll about 28 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 60 to 80; healthy volunteers accepted. Conditions: Healthy Aging; Lifestyle-related Condition; Metabolic Diseases.
Participants are able to provide signed and dated written informed consent prior to any study specific procedures
Aged ≥ 60 and ≤ 80 years
Body mass index (BMI) 25 - 35 kg/m2
Stable dietary habits (no weight loss or gain > 5 kg in the past 3 months)
1 more inclusion criterion and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
The prevalence of age-related chronic diseases (like obesity, type 2 diabetes and cardiovascular diseases) is mounting worldwide, reaching pandemic proportions. These age-related chronic diseases are associated with diminished skeletal muscle mitochondrial function in humans. Nicotinamide adenosine dinucleotide (NAD) is a coenzyme that regulates mitochondrial function, therefore, plays an important role in energy metabolism. Importantly, it has been shown that high cellular NAD+ levels as well as a high NAD+/NADH ratio promote metabolic and mitochondrial health. The full summary is on the listing.
Where, as registered
No US site; Chile (1).
RecruitingNCT06971224
NADream: Effects of Nicotinamide Adenine Dinucleotide Supplementation on Sleep Quality in Healthy Individuals
Phase 2
Haukeland University Hospital
About 16 people
Starts Oct 13, 2025 (estimated)
In plain words A Phase 2 study of nicotinamide riboside in people 40 to 60, run by Haukeland University Hospital. It plans to enroll about 16 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 40 to 60; healthy volunteers accepted. Conditions: Sleep.
Participant must be 40 to 60 years of age inclusive, at the time of signing the informed consent.
Male or female.
Participants who are healthy as determined by medical evaluation including medical history and physical examination.
Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the study protocol.
3 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
The purpose of this study is to evalue the effects of nicotinamide adenine dinucleotide (NAD) supplementation (nicotinamide riboside (NR) form) on sleep in healthy adults compared to a placebo. NAD is important for brain health and energy balance and a proposed explanation for its effect on sleep is that NAD supplementation restores the neurophysiological capacity of the brain to 'rest' during sleep. If this is the case, we expect the administration to result in improvements in sleep quality (and most likely sleep quantity) compared to placebo. The full summary is on the listing.
Where, as registered
No US site; Norway (1).
RecruitingNCT07344636
Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training
No phase
ZHANG Jiaqi
About 16 people
Started Jan 6, 2026
In plain words A study of nicotinamide riboside in people 18 to 80, run by ZHANG Jiaqi. It plans to enroll about 16 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists people 18 to 80; healthy volunteers accepted. Conditions: Health Adult Subjects.
Zone 2 training, a low-intensity endurance exercise performed at approximately 66-80% of VO₂max or near the first ventilatory threshold, has gained popularity for improving aerobic capacity, fat metabolism, and mitochondrial efficiency. It preserves glycogen stores and delays fatigue, making it an essential training method for both athletes and recreational exercisers. Nicotinamide adenine dinucleotide (NAD) is a vital metabolite that regulates cellular energy metabolism and redox homeostasis. The full summary is on the listing.
Where, as registered
No US site; China (1).
RecruitingNCT07024966
Effect of the Combination of Pterostilbene Cocrystal With Silybin and Nicotinamide Riboside on Exercise-Induced Oxidative Stress
No phase
Fundació Eurecat
About 14 people
Started Aug 1, 2025
In plain words A study of nicotinamide riboside in male participants 18 to 50, run by Fundació Eurecat. It plans to enroll about 14 people at 1 site, none in the US.
Who it lists and where
Who the trial lists, as registered
Lists male participants 18 to 50; healthy volunteers accepted. Conditions: Oxidative Stress; Physical Activity; Antioxidant Effect.
Male participants between 18 and 50 years of age who are amateur runners.
Engage in at least 3 continuous running sessions per week, each lasting 60 minutes, which corresponds to a high level of physical activity according to the International Physical Activity Questionnaire (IPAQ).*
Self-report being able to continuously run for 45 minutes at high intensity without difficulty.
Provide signed informed consent prior to participation in the study.
2 more inclusion criteria and the exclusion criteria are on the listing.
What it tests, as registered
Pterostilbene-silybin-nicotinamide riboside; Control Group
Registered summary
This study aims to evaluate the effects of the dietary supplement ccPT-SIL-NR, which contains pterostilbene (ccPT), silybin (SIL), and nicotinamide riboside (NR), on oxidative stress markers after a high-intensity exercise session. The primary objective is to assess changes in blood malondialdehyde (MDA) levels. The full summary is on the listing.
Where, as registered
No US site; Spain (1).
Not yet recruitingNCT07693543
Nicotinamide Riboside Supplementation in Chronic Kidney Disease
Phase 2
University of California, San Diego
About 30 people
Starts Oct 1, 2026 (estimated)
In plain words A Phase 2 study of nicotinamide riboside in people 30 and older, run by University of California, San Diego. It plans to enroll about 30 people at 1 US site.
Who it lists and where
Who the trial lists, as registered
Lists people 30 and older. Conditions: Chronic Kidney Disease.
Moderate chronic kidney disease not treated with dialysis, defined as eGFR 30-59 mL/min/1.73 m2 using the CKD-EPI equation.
Urine albumin-to-creatinine ratio (uACR) <300 mg/g.
Able to provide informed consent.
Able to walk unassisted from room to room, with usual assistive device allowed if approved by study safety assessment.
1 more inclusion criterion and the exclusion criteria are on the listing.
This study is testing whether a dietary supplement called nicotinamide riboside, (NR), can be used in adults with moderate chronic kidney disease. NR is a form of vitamin B3 that may help support cellular energy metabolism. The main goal of this study is to see whether it is feasible for people with chronic kidney disease to take NR daily, complete study visits, and follow the study procedures. The study will also explore whether NR chloride affects markers of mitochondrial health, small blood vessel function, and physical function. The full summary is on the listing.
Where, as registered
1 US site in 1 state.
Not yet recruitingNCT07782671
The NICE-PAD II Trial
Phase 3
Northwestern University
About 250 people
Starts Dec 2026 (estimated)
In plain words A Phase 3 study of nicotinamide riboside in people 50 and older, run by Northwestern University. It plans to enroll about 250 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists people 50 and older. Conditions: Peripheral Artery Disease (PAD).
1\. Age 50 and older.
2\. Presence of peripheral artery disease (PAD). PAD will be defined as either: a. An ABI < 0.90 at baseline. b.
The exclusion criteria are on the listing.
What it tests, as registered
Nicotinamide Riboside (NR); Placebo
Registered summary
Among people with peripheral artery disease (PAD) age 50 and older, the investigators will test the hypothesis that PAD participants randomized to nicotinamide riboside (NR) will have greater improvement or less decline in six-minute walk distance at six-month follow-up, compared to those randomized to placebo. The study will randomize 250 participants with PAD age 50 and older to one of two groups for six months: nicotinamide riboside vs placebo. Our primary outcome is change in six-minute walk distance at six-month follow-up. The full summary is on the listing.
Where, as registered
No sites listed yet.
Not yet recruitingNCT07475208
NR and Exercise for Blood Pressure
No phase
ZHANG Jiaqi
About 112 people
Starts Apr 2026 (estimated)
In plain words A study of nicotinamide riboside in female participants 55 to 80, run by ZHANG Jiaqi. It plans to enroll about 112 people and lists no sites yet.
Who it lists and where
Who the trial lists, as registered
Lists female participants 55 to 80. Conditions: Hypertension (HTN).
women absent of menstruation for over one year,
Chinese, and
fulfill the criteria of elevated/stage I hypertension according to 2025 American College of Cardiology/American Heart Association Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (i.e.,…
Hypertension continues to pose a significant global health challenge, with rates of optimal blood pressure control remaining low - particularly in China, where fewer than 5% of individuals with hypertension achieve guideline-recommended targets. Age-associated endothelial dysfunction and arterial stiffness are recognized as the key contributors to the development of hypertension and the unique role of nicotinamide adenine dinucleotide (NAD) depletion in the pathogenesis of vascular dysfunction has been recently discovered. The full summary is on the listing.
Where, as registered
No sites listed yet.
ClinicalTrials.gov lists 38 open registrations for this search, including ones where nicotinamide riboside is not a study arm or that are past the 28 we keep. Search them on ClinicalTrials.gov (opens in new tab).